Reporting owner · CIK 0001134657

Evnin Luke

Visual SEC Form 4 history across 3 companies, 25 transactions and 6 filings.

10%Entrada Therapeutics, Inc.
Open-market mix
Latest filingAug 31, 2026, 10:25 PM
Filings6Form 4 records
Buying$20M1 purchases
Selling$1.2M15 sales
Net value$18.8MBuys minus sells
Companies34 securities
Most recentAug 31, 2026sale

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for some of their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
1050-5-102Dec 2514Jan 263May 266Aug 26

Net value flow

Buys minus sells

Dec 25
−$36.7K
Jan 26
$20M
May 26
−$66.2K
Aug 26
−$1.1M

Transaction texture

Ownership and ticket size

Average P/S size$1.3M
Median P/S size$26.3K
Direct0
Indirect25
Aug 31, 2026sale

Filing-only signals

Deterministic matches in this insider's history

Cluster Buypattern1Cluster Sellingpattern6Derivative Transactionfiling-context3Large Buysize1Large Holdings Increaseholdings4Large Salesize1Repeat Sellerpattern510b5-1 Detectedfiling-context910% Owner Buyrole1

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Entrada Therapeutics, Inc. on Aug 31, 2026 valued at $309,370.

Review SEC filing
Latest buy

buy at Aktis Oncology, Inc. on Jan 12, 2026 valued at $20,029,986.

Review SEC filing
Latest sale

sale at Entrada Therapeutics, Inc. on Aug 31, 2026 valued at $309,370.

Review SEC filing

Associated companies

Visual map of known reporting history

TRDAEntrada Therapeutics, Inc.6 transactions · latest Aug 31, 2026, 10:25 PMHOWLWerewolf Therapeutics, Inc.9 transactions · latest May 29, 2026, 10:51 PMAKTSAktis Oncology, Inc.10 transactions · latest Jan 14, 2026, 11:19 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
TRDAEVNIN LUKE
10%
sale44.2k-$30.9MS
Cluster Selling Repeat Seller
0.0%08/3108/31
TRDAEVNIN LUKE
10%
sale3.73k-$2.61MS
Cluster Selling Repeat Seller
0.0%08/3108/28
TRDAEVNIN LUKE
10%
sale38.9k-$28.0MS
Cluster Selling Repeat Seller
0.0%08/3108/27
TRDAEVNIN LUKE
10%
sale14.5k-$10.2MS
Cluster Selling Repeat Seller
—08/2708/26
TRDAEVNIN LUKE
10%
sale26.5k-$19.9MS
Cluster Selling Repeat Seller
—08/2708/25
TRDAEVNIN LUKE
10%
sale21.6k-$15.8MS
Cluster Selling
—08/2708/24
HOWLEVNIN LUKE
DIR
sale10b5-132.5k-$1.46MS
10b5-1 Detected
+93.3%05/2905/29
HOWLEVNIN LUKE
DIR
sale10b5-127.6k-$1.27MS
10b5-1 Detected
+93.3%05/2905/28
HOWLEVNIN LUKE
DIR
sale10b5-180.8k-$3.88MS
Large Sale 10b5-1 Detected
+93.3%05/2905/27
AKTSEVNIN LUKE
10%
unknown1.57M—C——01/1401/12

Evnin Luke Insider Activity FAQ

SEC Form 4 context

Who is Evnin Luke?

Evnin Luke is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001134657.

Which companies has Evnin Luke reported transactions for?

Entrada Therapeutics, Inc., Werewolf Therapeutics, Inc., Aktis Oncology, Inc.

When was Evnin Luke's latest insider buy?

buy at Aktis Oncology, Inc. on Jan 12, 2026 valued at $20,029,986.

When was Evnin Luke's latest insider sale?

sale at Entrada Therapeutics, Inc. on Aug 31, 2026 valued at $309,370.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.